

Anticoagulation in AF and coronary artery disease

李貽恆

國立成功大學醫學院附設醫院 心臟內科

Yi-Heng Li, MD, PhD, FESC, FACC
Chief and Professor, Division of Cardiology
Hospital & College of Medicine
National Cheng Kung University
Tainan, Taiwan

Atrial fibrillation and coronary artery disease occur in the same patient frequently. Adequate antithrombotic treatment is necessary to provide protection from acute cardiac ischemic event and stroke in these patients. The optimal antithrombotic regimen with balance of efficacy and safety on the risk of stroke and bleeding is still unknown. Current guideline or experts consensus recommend oral anticoagulant therapy for most patients with atrial fibrillation and consideration of triple therapy with oral anticoagulant and aspirin and clopidogrel when there is acute coronary syndrome or stent placement. However, triple therapy increases the risk of major bleeding. Randomized clinical trials are still undergoing to identify the optimal combination antithrombotic therapies in atrial fibrillation and coronary artery disease. This talk will take a real case as a demonstration of how we choose different antithrombotic therapies based on extrapolations from current existed randomized trials and observational studies.